JARDIANCE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(2 years from now) | |
| US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7713938 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Oct, 2027
(3 years from now) | |
|
US7579449 (Pediatric) | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Feb, 2029
(4 years from now) | |
| US8551957 | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Oct, 2029
(5 years from now) | |
|
US8551957 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Apr, 2030
(5 years from now) | |
| US10406172 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2030
(6 years from now) | |
| US11813275 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11833166 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11666590 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US9949997 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
May, 2034
(10 years from now) | |
| US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(10 years from now) | |
|
US11090323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(10 years from now) | |
|
US10258637 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(10 years from now) | |
|
US9949997 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Nov, 2034
(10 years from now) | |
|
US9949998 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Dec, 2034
(10 years from now) | |
Jardiance is owned by Boehringer Ingelheim.
Jardiance contains Empagliflozin.
Jardiance has a total of 18 drug patents out of which 0 drug patents have expired.
Jardiance was authorised for market use on 01 August, 2014.
Jardiance is available in tablet;oral dosage forms.
Jardiance can be used as treating type 2 diabetes mellitus by assessing renal function and orally administering empagliflozin in a daily amount of 10 mg or 25 mg if the egfr>=45 ml/min/1.73 m2 and <60 ml/min/1.73 m2, wherein the treatment improves glycemic control, method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin, method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin, method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin, treatment and reduction of risk by administration of empagliflozin to adults with chronic kidney disease at risk of progression, method for reducing the risk of cardiovascular death and hospitalization in patients with heart failure by administration of empagliflozin, method for reducing the risk of cardiovascular death plus hospitalization for heart failure in adults with type 2 diabetes mellitus, heart failure and reduced ejection fraction by once daily administration of empagliflozin, method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin.
Drug patent challenges can be filed against Jardiance from 20 December, 2025.
The generics of Jardiance are possible to be released after 11 December, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 20, 2026 |
| New Indication(I-869) | Aug 18, 2024 |
| New Indication(I-922) | Sep 21, 2026 |
| M(M-82) | Feb 24, 2025 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| M(M-159) | Jun 26, 2018 |
| New Indication(I-739) | Dec 02, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| M(M-160) | Jun 26, 2018 |
| M(M-161) | Jun 26, 2018 |
| M(M-174) | Mar 18, 2019 |
Drugs and Companies using
EMPAGLIFLOZIN ingredient
NCE-1 date:
Market Authorisation Date:
01 August, 2014Treatment:
Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with...Dosage:
How can I launch a generic of JARDIANCE before its drug patent expiration?
More Information on Dosage
JARDIANCE family patents
